Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 605 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Arthur Levin sold 605 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $36.80, for a total transaction of $22,264.00. Following the completion of the sale, the director directly owned 4,237 shares in the company, valued at $155,921.60. This trade represents a 12.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Stoke Therapeutics Stock Down 3.2%

Shares of STOK traded down $1.09 during mid-day trading on Tuesday, reaching $32.87. 694,722 shares of the company’s stock were exchanged, compared to its average volume of 750,800. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $40.22. The company has a market cap of $1.88 billion, a price-to-earnings ratio of 49.06 and a beta of 1.07. The company has a 50-day simple moving average of $32.74 and a two-hundred day simple moving average of $29.80.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, March 17th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.22). The company had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $5.32 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. As a group, equities research analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its position in Stoke Therapeutics by 333.8% during the fourth quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock worth $46,031,000 after buying an additional 1,116,452 shares during the period. State Street Corp grew its holdings in Stoke Therapeutics by 75.2% in the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock valued at $79,288,000 after buying an additional 1,072,176 shares during the period. Corient Private Wealth LLC acquired a new position in shares of Stoke Therapeutics during the 2nd quarter valued at about $7,489,000. BVF Inc. IL increased its stake in shares of Stoke Therapeutics by 36.7% during the 4th quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock valued at $71,912,000 after acquiring an additional 608,578 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Stoke Therapeutics by 438.2% during the 3rd quarter. Wellington Management Group LLP now owns 737,753 shares of the company’s stock worth $17,337,000 after acquiring an additional 600,687 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Canaccord Genuity Group lifted their price objective on Stoke Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. UBS Group set a $50.00 price target on shares of Stoke Therapeutics in a research note on Monday, December 15th. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a report on Monday, January 5th. Guggenheim assumed coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They issued a “buy” rating and a $60.00 price objective for the company. Finally, Wedbush upped their price objective on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Stoke Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $39.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.